ConductScience.org, home

Paper42909255PubMed

Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death.

Levchuk K and 6 others. Front Immunol, 2026.

Cite this record

ConductScience Library. Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death. Papers, record 42909255. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42909255

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death.
Journal
Front Immunol
Year
2026
Publication types
Journal Article, Review
Revised in PubMed
2026-10-24

Source PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Levchuk KKsenia
2Petukhov AAlexey
3Tursymbek SShynggys
4Seitkamal KKuanysh
5Bertleuova AArailym
6Bulanin DDenis
7Barlev NANikolai A

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ChemokinesMajor topic
NeoplasmsMajor topic
Immunotherapy, AdoptiveMajor topic
Receptors, Chimeric AntigenMajor topic
T-LymphocytesMajor topic
Humans
Animals
Cell Movement
Cell Death
Tumor Microenvironment
Signal Transduction

Source PubMed

Download CSV of topics

References180

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129311381Metabolic Barriers to T Cell Function in Tumors.J Immunol2018https://conductscience.org/library/papers/29311381PubMed
228486109Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.Cancer Cell2017https://conductscience.org/library/papers/28486109PubMed
334083764T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.Nat Biomed Eng2021https://conductscience.org/library/papers/34083764PubMed
433262763A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy.Front Immunol2020https://conductscience.org/library/papers/33262763PubMed
537058548Metabolic challenges and interventions in CAR T cell therapy.Sci Immunol2023https://conductscience.org/library/papers/37058548PubMed
617667919Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation.Br J Cancer2007https://conductscience.org/library/papers/17667919PubMed
7259390634-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.Nat Med2015https://conductscience.org/library/papers/25939063PubMed
833020644Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.Nat Med2020https://conductscience.org/library/papers/33020644PubMed
919847165Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.Nature2009https://conductscience.org/library/papers/19847165PubMed
1037248395Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity.Nat Cancer2023https://conductscience.org/library/papers/37248395PubMed
1139471818Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias.Cell Rep Med2024https://conductscience.org/library/papers/39471818PubMed
1234325726IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.J Hematol Oncol2021https://conductscience.org/library/papers/34325726PubMed
1337130030Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction.Blood2023https://conductscience.org/library/papers/37130030PubMed
1442250288CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth.Int Immunopharmacol2026https://conductscience.org/library/papers/42250288PubMed
1537603742The spread of interferon-γ in melanomas is highly spatially confined, driving nongenetic variability in tumor cells.Proc Natl Acad Sci U S A2023https://conductscience.org/library/papers/37603742PubMed
1637851569Functional diversification and dynamics of CAR-T cells in patients with B-ALL.Cell Rep2023https://conductscience.org/library/papers/37851569PubMed
1728650338IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.J Clin Invest2017https://conductscience.org/library/papers/28650338PubMed
1842368560Targeting cytokine/chemokine signaling to convert immunologically cold tumors into hot: Emerging strategies in cancer immunotherapy.Acta Pharm Sin B2026https://conductscience.org/library/papers/42368560PubMed
1935675405Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL.Sci Adv2022https://conductscience.org/library/papers/35675405PubMed
2041533516In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment.Cell Rep2026https://conductscience.org/library/papers/41533516PubMed

See all 180 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42909255

GET https://conductscience.org/api/papers/v1/42909255/references?page=2